Clinical Pearls

Bite-sized clinical takeaways from today's literature (sources from Oct 29 – May 25)

• Prescribe z-drugs or DORAs as first-line pharmacotherapy for primary insomnia to minimize the risk of tolerance associated with benzodiazepines.
• Consider off-label agents rather than z-drugs when treating secondary insomnia, as the prescribing principles for sedative-hypnotics differ based on the underlying etiology.
• Reassure patients undergoing rTMS that treatment-emergent headaches, while more common in younger females with severe baseline depression, do not predict poorer clinical response or treatment retention.
• Counsel male patients of reproductive age that ADHD stimulant use is associated with reduced semen volume, acknowledging this potential reproductive side effect.
• Monitor for potential negative symptom improvement in schizophrenia patients, as preclinical data suggest the phytocannabinoid cannabidivarin may alleviate cognitive and social deficits.
• Note that psilocybin modulates social behavior in a time-dependent manner, providing mechanistic insight into its potential utility for treating social deficits in psychiatric conditions.
• Evaluate the risk-benefit ratio of psychostimulants in men concerned about fertility, given emerging data linking use to reduced semen volume.
• Utilize the association of rTMS headaches with younger age and female sex to anticipate and preemptively manage side effects in high-risk demographics.
• Recognize that preclinical evidence supports the exploration of cannabidivarin for negative symptoms in schizophrenia, warranting future clinical investigation.
• Distinguish between primary and secondary insomnia when selecting hypnotics, as the guidelines explicitly favor z-drugs/DORAs for primary cases while allowing off-label flexibility for secondary causes.